Postop events suggest need for ‘attentive’ management after Xen implantation

A retrospective study of eyes implanted with the Allergan Xen45 gel stent supports evidence that the device can significantly reduce IOP as well as medication burden in patients with glaucoma, although the number of postoperative interventions recorded suggested a need for “attentive postoperative management.”
Researchers at the Medical University of Graz implanted the surgical device in 199 eyes of 160 patients between 2014 and 2016. In 89 eyes followed up at 12 months, mean IOP reduction was 22.7%, from 22.8 mm Hg preoperatively to 17.1 mm Hg (P < .0001). (Read more...)

Full Story →